Newsroom | etectRx

Recap with ID-Cap®: Monitoring HIV Medication Adherence in University of Colorado’s QUANTI-TAF Study

In collaboration with the University of Colorado, etectRx has made significant strides in advancing medication adherence monitoring through the QUANTI-TAF study (NCT04065347). Recently published in Clinical Infectious Diseases1 and the British Journal of Clinical Pharmacology2, the QUANTI-TAF study focused on antiretroviral therapy (ART) adherence among persons with HIV (PWH) receiving daily oral tenofovir alafenamide/emtricitabine (TAF/FTC)-based ART for at least

March 3, 2025

ID Cap™ System Evolution: Introducing the Wrist-Worn Reader

The development of a Wrist-Worn Reader is the latest advancement to the ID-Cap™ System, offering a promising solution to address the complex issue of medication non-adherence. Medication nonadherence is a widespread problem, resulting in significant healthcare costs and challenges for individuals managing chronic conditions. In particular, adherence is crucial in the context of HIV prevention, where

November 6, 2023

ID-Cap™ System Powers Historic HIV Digital Pill Study

etectRx announces record-breaking use of the ID-Cap™ System, utilized in University of Colorado’s HIV treatment study. The Quantification of Tenofovir Alafenamide Adherence and Exposure in Adults living with HIV (QUANTI-TAF) study evaluated drug concentrations in dried blood spots (DBS), in tandem with medication adherence measured by the ID-Cap™ System. The ID-Cap™ System’s remote patient monitoring

October 9, 2023

AARDEX® Group Adds etectRx to their MEMS® Adherence Hardware Ecosystem

The partnership sees the integration of AARDEX’s adherence analytics software with etectRx’s ingestible adherence sensor Liege, Belgium (APRIL 28th, 2022) – Belgium-based AARDEX® Group, the leader in measuring and managing medication adherence in clinical trials today announced a strategic partnership with etectRx, Inc. This new collaboration combines etectRx’s ingestible event marker, the ID-Cap™ System, and

April 29, 2022

WHITEPAPER: The Extraordinary Problem of Medication Nonadherence in Oncology Patients And How Digital Pills Can Make a Difference

Cancer is often highly treatable due to new therapies, especially oral agents, that have improved outcomes and survival rates, and allow patients to be treated outside the hospital setting. Yet many patients fail to take their medication consistently, despite the potentially dire consequences of not adhering to the prescribed oncology treatment plan. Nonadherence or suboptimal

May 4, 2021

etectRx “It Already Does That”

Inspiration struck the etectRx team after watching the Apple Watch Series 6 – “It Already Does That” campaign. etectRx enthusiastically created its version of “It Already Does That” highlighting our FDA cleared ID-Cap™ System. We are passionate about the need to empower patients and expand the connection a person has to their own healthcare, while

April 30, 2021

The ID-Cap™ System: A Physician’s Perspective

“The overall experience of our study participants so far with the ID-Cap System has been very positive. They have been able to navigate it quite easily and be engaged with the system.” – Dr. Jose Castillo-Mancilla, MD, Physician and Clinical Researcher. In this video, Dr. Jose Castillo-Mancilla speaks about the importance of the connection between

April 14, 2021

Digital Pill Study Shows Significant Impact on Hepatitis C Treatment Adherence and Efficacy

A study conducted between August 2017 and April 2019 with 288 participants for hepatitis C virus (HCV) treatment evaluated the impact of a digital medicine program (DMP) on medication adherence (Proteus Digital Health) in a population at risk for nonadherence. The study was a prospective, single-arm, open-label study at 18 US academic and community clinics. All

March 5, 2021

Failure Risk in Clinical Trials? An Easy-to-Swallow Solution

Our CEO Valerie Sullivan speaks in PharmaVOICE about failing clinical trials and our easy solution: the etectRx digital pill ID-Cap™ System. With our technology, there is no reason for clinical trial failure, and with growing remote patient monitoring and telehealth, our technology is a safe, effective and FDA cleared solution. Read Full Article

February 19, 2021

Better Connections with Patients Using Data from Digital Pills

etectRx hosted an Xtalks Webinar on December 3: “Better Connections with Patients Using Data from Digital Pills.” Susan Baumgartner, VP of Product Management and Regulatory Affairs at etectRx, started the discussion speaking about medication nonadherence, the need for digital pills and the ease of using our ID-Cap™ System. Dr. Peter Chai, a long-time collaborator of

December 17, 2020